next-generation IL-12 inhibitors (Synta)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug Namenext-generation IL-12 inhibitors (Synta)
Drug Alias NameSTA-4953
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionInterleukin-12 receptor inhibitors
TargetsInterleukin-12 receptor
Therapy Area/IndicationsInflammationAutoimmune Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesMadrigal Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMadrigal Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsInflammationAutoimmune Diseases

Other Information

ATC CodeN/A
Related LinksN/A